Sandu Pharmaceuticals
40.40
+0.89(+2.25%)
Market Cap₹- Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D+2.25%
1M-8.70%
6M-21.12%
1Y-30.34%
5Y+22.42%
View Company Insightsright
More news about Sandu Pharmaceuticals
16Jun 25
Sun Pharma's Halol Facility Faces FDA Scrutiny; Leadership Transition Announced
Sun Pharmaceuticals received eight FDA observations for its Halol facility, which is already under import alert. The company also announced a leadership transition, with Kirti Ganorkar set to become Managing Director on September 1, 2025, succeeding founder Dilip Shanghvi.
Sandu Pharmaceuticals
40.40
+0.89
(+2.25%)
1 Year Returns:-30.34%
Industry Peers
Windlas Biotech
790.15
(+0.55%)
Jeena Sikho Lifecare
699.20
(+0.52%)
Blue Jet Healthcare
554.80
(-2.56%)
Abbott
28,850.00
(-0.14%)
Sunrest Lifescience
42.05
(-2.21%)
Zenith Drugs
54.60
(+2.25%)
Pfizer
5,001.00
(+0.57%)
FDC
414.10
(+0.24%)